Abbott & #039;s FreeStyle Gets Real-World Results

It's been just a little more than eight months since FDA approved Abbott's FreeStyle Libre system, which has already proven to be a blockbuster product for the company. In January, Abbott CEO Miles White said the company is adding 300,000 new Freestyle Libre patients per quarter and growing. More than 1.5 million people are currently using the continuous glucose monitoring system across 46 countries. Now it's time to find out how much of an impact the FreeStyle Libre system actually has on glycemic control in people on intensive insulin therapy living with Type 2 diabetes. Judging by new data presented at the American Diabetes Association's annual meeting this week in San Francisco, CA, it appears that the device has indeed made a difference for patients. Researchers evaluated de-identified records of 363 individuals across France, Germany, and Austria, assessing their hemoglobin A1c (HbA1c) levels over three months to six months in people averaging about 63 years in age who use insulin multiple times a day for an average of more than eight years. The results – which represent the first time researchers evaluated real-world data specifically from people with Type 2 diabetes who use the FreeStyle Libre system  – showed lower HbA1c levels with the use of Abbott's technology after at least three months of use. The nearly 1% drop (-0.9% or -9.7 mmol/mol) in HbA1c represents a significant reduction of glucose ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news